Nivolumab with or without axitinib after prior nivolumab
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer that is mainly clear-cell type, confirmed by lab tests
- You already completed nivolumab plus ipilimumab and are not fully in remission and not worsening
- You have at least one measurable tumor spot on scans
- Your general health is good (performance status 0 or 1)
- Your blood tests and organ function (liver/kidney/bone marrow) meet specific minimum levels
- You have usable tumor tissue on file and can follow study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.